About a week after AtheroGenics Inc. disclosed in SEC paperwork that the firm is saying goodbye to about half its work force, and slightly more than a month after partner AstraZeneca plc bailed out of a major deal for AGI-1067, the Phase III focus for that compound is shifting from atherosclerosis to diabetes. (BioWorld Today) Read More
